Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Initial therapy for early ovarian carcinoma.

R C Young1

  • 1Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892.

Cancer
|October 15, 1987
PubMed
Summary

Accurate surgical staging is crucial for early ovarian cancer. It helps identify patients needing adjuvant therapy, improving survival rates and avoiding unnecessary treatments for those with good prognoses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The sounds of silence.

Nature·2000
Same author

Cervical epidermal growth factor-receptor (EGF-R) and serum insulin-like growth factor II (IGF-II) levels are potential markers for cervical cancer.

American journal of reproductive immunology (New York, N.Y. : 1989)·2000
Same author

Automated oxyhemoglobin dissociation curve construction to assess sickle cell anemia therapy.

Journal of the National Medical Association·2000
Same author

Up-regulation of epidermal growth factor-receptors (EGF-R) by nicotine in cervical cancer cell lines: this effect may be mediated by EGF.

American journal of reproductive immunology (New York, N.Y. : 1989)·2000
Same author

Fox Chase Network: Fox Chase Cancer Center's community hospital affiliation program.

The oncologist·2000
Same author

Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer.

Seminars in oncology·2000

Area of Science:

  • Gynecologic Oncology
  • Surgical Oncology
  • Clinical Trials

Background:

  • Early epithelial ovarian cancer (FIGO Stages I and II) accounts for 33% of invasive cases in the US.
  • Understaging is common, with only 25% of surgeries adequately evaluating the entire abdominal cavity.
  • Incomplete staging leads to residual disease in 33% of patients, often spread intraabdominally.

Purpose of the Study:

  • To emphasize the importance of thorough operative staging in early ovarian cancer.
  • To define patient subsets who require adjuvant therapy versus those who do not.
  • To improve survival rates through accurate staging and targeted adjuvant treatments.

Main Methods:

  • Review of surgical staging studies in early epithelial ovarian cancer.
  • Analysis of outcomes based on the accuracy of initial surgical staging.
  • Evaluation of prospective clinical trials testing various adjuvant therapies (chemotherapy, 32P, whole abdominal irradiation).

Main Results:

  • Comprehensive surgical staging identifies early ovarian cancer patients with prognoses (90-95% 5-year survival) not requiring adjuvant therapy.
  • Inaccurate staging leads to poor survival rates for Stage I (70%) and Stage II (40-50%) disease, necessitating adjuvant treatment.
  • Adjuvant therapies like chemotherapy, 32P, or whole abdominal irradiation show potential to eradicate micrometastases.

Conclusions:

  • Accurate surgical staging is essential for determining the need for adjuvant therapy in early ovarian cancer.
  • Targeted adjuvant therapy for high-risk areas improves survival.
  • Identifying patients who do not require further treatment reduces the risk of late second malignancies.

Related Experiment Videos